Literature DB >> 23715693

Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review.

Dan Chen1, Xiao-bing Wang, Yan Zhou, Xiao-chun Zhu.   

Abstract

This retrospective study assessed the efficacy of infliximab therapy in 14 patients with dermatomyositis with acute interstitial pneumonia. Ten patients starting treatment at an early stage of the disease achieved satisfactory relief, while four patients treated at a late stage failed to respond to the treatment and died.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23715693     DOI： 10.1007/s00296-012-2653-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  8 in total

1.  Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis.

Authors:  Adla B Hassan; Liene Nikitina-Zake; Carani B Sanjeevi; Ingrid E Lundberg; Leonid Padyukov
Journal:  Arthritis Rheum       Date:  2004-03

2.  Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.

Authors:  Su-yun Ji; Fan-qin Zeng; Qing Guo; Guo-zhen Tan; Hong-feng Tang; Yi-jin Luo; Zeng-qi Tang; Yan-fang Han
Journal:  Chin Med J (Engl)       Date:  2010-03-05       Impact factor: 2.628

3.  Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.

Authors:  Hideto Kameda; Hayato Nagasawa; Hiroe Ogawa; Naoya Sekiguchi; Hirofumi Takei; Michihide Tokuhira; Koichi Amano; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

4.  Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Authors:  Shuang Ye; Xiao-xiang Chen; Xiao-ye Lu; Mei-fang Wu; Yun Deng; Wen-qun Huang; Qiang Guo; Cheng-de Yang; Yue-ying Gu; Chun-de Bao; Shun-le Chen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

5.  Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Takashi Satoh; Masataka Kuwana; Yasuhiro Katsumata; Kae Takagi; Ikuko Masuda; Akiko Tochimoto; Sayumi Baba; Yuko Okamoto; Yuko Ota; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-05-23       Impact factor: 7.580

Review 6.  Skin involvement in dermatomyositis.

Authors:  Beth Santmyire-Rosenberger; Elizabeth M Dugan
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

Review 7.  Treatment of the inflammatory myopathies: update and practical recommendations.

Authors:  Gerald J D Hengstman; Frank H J van den Hoogen; Baziel G M van Engelen
Journal:  Expert Opin Pharmacother       Date:  2009-05       Impact factor: 3.889

8.  Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.

Authors:  M Fathi; M Dastmalchi; E Rasmussen; I E Lundberg; G Tornling
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103
  8 in total
  12 in total

Review 1.  [Off-label use of infliximab].

Authors:  M Onder; C Salavastru; K Fritz
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

Review 2.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

Review 3.  [Dermatomyositis and juvenile dermatomyositis].

Authors:  Frank Dressler; Britta Maurer
Journal:  Z Rheumatol       Date:  2022-04-29       Impact factor: 1.372

Review 4.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623

Review 5.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

Review 6.  Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.

Authors:  Boel De Paepe; Jana Zschüntzsch
Journal:  Int J Mol Sci       Date:  2015-08-11       Impact factor: 5.923

Review 7.  Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hidenaga Kawasumi; Takahisa Gono; Yasushi Kawaguchi; Hisashi Yamanaka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-07-23

8.  Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui; Shinyu Izumi; Takashi Sozu
Journal:  BMJ Open       Date:  2018-12-16       Impact factor: 2.692

9.  Angiogenesis and VEGF-expressing cells are identified predominantly in the fascia rather than in the muscle during the early phase of dermatomyositis.

Authors:  Ken Yoshida; Haruyasu Ito; Kazuhiro Furuya; Taro Ukichi; Kentaro Noda; Daitaro Kurosaka
Journal:  Arthritis Res Ther       Date:  2017-12-08       Impact factor: 5.156

10.  The potential role of TNFα in 2019 novel coronavirus pneumonia.

Authors:  Wenjing Ye; Saisai Lu; Ali Xue
Journal:  Respir Med Case Rep       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.